FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2168017102> ?p ?o ?g. }

• W2168017102 endingPage "4152" @default.
• W2168017102 startingPage "4147" @default.
• W2168017102 abstract "ABSTRACT Nevirapine is a nonnucleoside reverse transcriptase inhibitor used as part of combination therapy for human immunodeficiency virus (HIV) infection. Nevirapine may be prescribed for patients with hepatic fibrosis and cirrhosis. Significant autoinduction of cytochrome P450 3A4 and 2B6 following multiple dosing prompted an assessment of the metabolic profiles in patients with liver disease receiving chronic nevirapine therapy. HIV-infected patients with hepatic fibrosis who were receiving a stable antiretroviral regimen containing nevirapine for ≥6 weeks had liver biopsy specimens assessed by Ishak histologic scoring and were grouped by severity (group 1, Ishak scores of 1 and 2; group 2, Ishak scores of 3 and 4; group 3, Ishak scores of 5 and 6). Steady-state trough nevirapine levels were determined for all patients, and additional measurements were obtained at 1, 2, and 4 h following nevirapine dosing for a subset of patients. The pharmacokinetics of nevirapine and its five metabolites were characterized, and a comparison of the results for the different Ishak groups was performed. Among 51 patients with hepatic fibrosis, the majority of whom were coinfected with hepatitis C virus or hepatitis B virus, differences between the maximum and the minimum observed plasma concentrations demonstrated a statistically significant flattening of the systemic exposure curves with progression from Ishak group 1 to Ishak group 2 or 3, suggesting a decrease in systemic clearance with the progression of liver disease. However, there were no significant differences in the trough and the maximum nevirapine concentrations between the Ishak groups. The metabolite profiles were also comparable across the Ishak groups. In HIV-infected patients who were chronically treated with nevirapine and who had various degrees of hepatic fibrosis, including cirrhosis, trough plasma nevirapine concentrations were not significantly increased, and thus, no dose adjustment is warranted." @default.
• W2168017102 created "2016-06-24" @default.
• W2168017102 creator A5007592771 @default.
• W2168017102 creator A5017620560 @default.
• W2168017102 creator A5030725109 @default.
• W2168017102 creator A5045416293 @default.
• W2168017102 creator A5056578595 @default.
• W2168017102 creator A5057724971 @default.
• W2168017102 creator A5090868285 @default.
• W2168017102 date "2009-10-01" @default.
• W2168017102 modified "2023-09-27" @default.
• W2168017102 title "Pharmacokinetic Assessment of Nevirapine and Metabolites in Human Immunodeficiency Virus Type 1-Infected Patients with Hepatic Fibrosis" @default.
• W2168017102 cites W1963569082 @default.
• W2168017102 cites W1981900811 @default.
• W2168017102 cites W2028358258 @default.
• W2168017102 cites W2036891173 @default.
• W2168017102 cites W2037606642 @default.
• W2168017102 cites W2062829031 @default.
• W2168017102 cites W2094360047 @default.
• W2168017102 cites W2108571082 @default.
• W2168017102 cites W2159248641 @default.
• W2168017102 cites W2167794954 @default.
• W2168017102 cites W2168998760 @default.
• W2168017102 cites W4239982842 @default.
• W2168017102 cites W4292079232 @default.
• W2168017102 doi "https://doi.org/10.1128/aac.00460-09" @default.
• W2168017102 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2764227" @default.
• W2168017102 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19620337" @default.
• W2168017102 hasPublicationYear "2009" @default.
• W2168017102 type Work @default.
• W2168017102 sameAs 2168017102 @default.
• W2168017102 citedByCount "16" @default.
• W2168017102 countsByYear W21680171022012 @default.
• W2168017102 countsByYear W21680171022013 @default.
• W2168017102 countsByYear W21680171022014 @default.
• W2168017102 countsByYear W21680171022015 @default.
• W2168017102 countsByYear W21680171022016 @default.
• W2168017102 countsByYear W21680171022017 @default.
• W2168017102 countsByYear W21680171022018 @default.
• W2168017102 countsByYear W21680171022020 @default.
• W2168017102 countsByYear W21680171022021 @default.
• W2168017102 crossrefType "journal-article" @default.
• W2168017102 hasAuthorship W2168017102A5007592771 @default.
• W2168017102 hasAuthorship W2168017102A5017620560 @default.
• W2168017102 hasAuthorship W2168017102A5030725109 @default.
• W2168017102 hasAuthorship W2168017102A5045416293 @default.
• W2168017102 hasAuthorship W2168017102A5056578595 @default.
• W2168017102 hasAuthorship W2168017102A5057724971 @default.
• W2168017102 hasAuthorship W2168017102A5090868285 @default.
• W2168017102 hasBestOaLocation W21680171022 @default.
• W2168017102 hasConcept C112705442 @default.
• W2168017102 hasConcept C126322002 @default.
• W2168017102 hasConcept C142462285 @default.
• W2168017102 hasConcept C203014093 @default.
• W2168017102 hasConcept C2522874641 @default.
• W2168017102 hasConcept C2775934546 @default.
• W2168017102 hasConcept C2777075537 @default.
• W2168017102 hasConcept C2777214474 @default.
• W2168017102 hasConcept C2777351918 @default.
• W2168017102 hasConcept C2777766500 @default.
• W2168017102 hasConcept C2779130552 @default.
• W2168017102 hasConcept C2780559512 @default.
• W2168017102 hasConcept C2781413609 @default.
• W2168017102 hasConcept C2993143319 @default.
• W2168017102 hasConcept C71924100 @default.
• W2168017102 hasConcept C90924648 @default.
• W2168017102 hasConcept C98274493 @default.
• W2168017102 hasConceptScore W2168017102C112705442 @default.
• W2168017102 hasConceptScore W2168017102C126322002 @default.
• W2168017102 hasConceptScore W2168017102C142462285 @default.
• W2168017102 hasConceptScore W2168017102C203014093 @default.
• W2168017102 hasConceptScore W2168017102C2522874641 @default.
• W2168017102 hasConceptScore W2168017102C2775934546 @default.
• W2168017102 hasConceptScore W2168017102C2777075537 @default.
• W2168017102 hasConceptScore W2168017102C2777214474 @default.
• W2168017102 hasConceptScore W2168017102C2777351918 @default.
• W2168017102 hasConceptScore W2168017102C2777766500 @default.
• W2168017102 hasConceptScore W2168017102C2779130552 @default.
• W2168017102 hasConceptScore W2168017102C2780559512 @default.
• W2168017102 hasConceptScore W2168017102C2781413609 @default.
• W2168017102 hasConceptScore W2168017102C2993143319 @default.
• W2168017102 hasConceptScore W2168017102C71924100 @default.
• W2168017102 hasConceptScore W2168017102C90924648 @default.
• W2168017102 hasConceptScore W2168017102C98274493 @default.
• W2168017102 hasIssue "10" @default.
• W2168017102 hasLocation W21680171021 @default.
• W2168017102 hasLocation W21680171022 @default.
• W2168017102 hasLocation W21680171023 @default.
• W2168017102 hasLocation W21680171024 @default.
• W2168017102 hasOpenAccess W2168017102 @default.
• W2168017102 hasPrimaryLocation W21680171021 @default.
• W2168017102 hasRelatedWork W103547024 @default.
• W2168017102 hasRelatedWork W1980748566 @default.
• W2168017102 hasRelatedWork W2001009580 @default.
• W2168017102 hasRelatedWork W2043383895 @default.
• W2168017102 hasRelatedWork W2092789309 @default.
• W2168017102 hasRelatedWork W2104682956 @default.
• W2168017102 hasRelatedWork W2149346967 @default.

• next